8-K
filed April 1, 2024, 7:59 PM ET
ticker VCNX
CIK 0001205922
other material
confidence high
sentiment neutral
materiality 0.75
Vaccinex raises ~$4.5M via multiple equity financings; issues Series A Preferred and warrants
VACCINEX, INC.
- Gross proceeds: ~$1.5M from RDO + PIPE (193K shares and warrants at $7.77/unit).
- Additional Private Placement: ~$1.25M from 159,683 shares and warrants at $7.77/unit; insiders participated.
- ADDF Transaction: $1.75M from Series A Preferred (5% cumulative dividend, convertible) and warrants for 229,057 shares.
- Warrants exercisable at $7.64/share, 5-year term; callable after positive SIGNAL-AD Alzheimer's data release.
- Lock-up on insiders through May 12, 2024; company restricted from most equity issuances until June 26, 2024.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
VACCINEX, INC.: Filed Certificate of Designation of Series A Preferred Stock to create and establish rights, preferences and terms of the series (effective 2024-03-29).
- Change
- charter amendment
- Effective
- 2024-03-29
Exact text from the filing
On March 29, 2024, the Company filed the Certificate of Designation of Series A Preferred Stock (the “Certificate”) with the Delaware Secretary of State, creating the Series A Preferred Stock and establishing the rights, preferences and other terms of the Series A Preferred Stock, and issued the Series A Preferred Stock.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
VACCINEX, INC. entered into RDO Purchase Agreement with purchasers named therein valued at aggregate gross proceeds of approximately $1.5 million (effective 2024-03-27).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- purchasers named therein
- Value
- aggregate gross proceeds of approximately $1.5 million
- Effective
- 2024-03-27
Exact text from the filing
On March 27, 2024, Vaccinex, Inc. (the “Company”) entered into a securities purchase agreement (the “RDO Purchase Agreement”) pursuant to which it agreed to issue and sell to the purchasers named therein (i) an aggregate of 193,000 shares (the “RDO Shares”) of the Company’s common stock (“Common Stock”) in a public offering and (ii) warrants (the “PIPE Warrants”) to purchase up to 193,000 shares of Common Stock in a concurrent private placement (collectively, the “AGP Transactions”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
VACCINEX, INC. entered into Advisory Agreement with A.G.P./Alliance Global Partners valued at cash fee equal to $140,000 and reimbursement of $75,000 (effective 2024-03-27).
- Action
- entry
- Counterparty
- A.G.P./Alliance Global Partners
- Value
- cash fee equal to $140,000 and reimbursement of $75,000
- Effective
- 2024-03-27
Exact text from the filing
In connection with the AGP Transactions, on March 27, 2024, the Company entered into a financial advisory agreement (the “Advisory Agreement”) with A.G.P./Alliance Global Partners (the “Financial Advisor”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
VACCINEX, INC. entered into Private Placement Purchase Agreement with Private Placement Investors valued at aggregate gross proceeds of approximately $1.25 million (effective 2024-03-27).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Private Placement Investors
- Value
- aggregate gross proceeds of approximately $1.25 million
- Effective
- 2024-03-27
Exact text from the filing
On March 27, 2024, the Company entered into a securities purchase agreement (the “Private Placement Purchase Agreement”) pursuant to which the Company agreed to issue and sell to the purchasers named therein (the “Private Placement Investors”) an aggregate of 159,683 shares (“Private Placement Shares”) of Common Stock together with warrants (“Private Placement Warrants”) to purchase up to 159,683 shares of Common Stock at a combined price of $7.77 per Private Placement Share and accompanying Private Placement Warrant (together, the “Private Placement Securities”) (the “Additional Private Placement”).
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.